Tirzepatide Cuts Time to Glycemic Targets by 4-12 Weeks vs Other Diabetes Therapies - Endocrinology Network

An analysis of data from SURPASS-2 and -3 provides evidence demonstrating the reduction in time to achieve glycemic targets and weight loss with use of tirzepatide compared with semaglutide 1.0 mg and long-acting insulin degludec.
A new analysis of data from the SURPASS program suggest use of tirzepatide (Mounjaro) could help people with diabetes reach glycemic targets in a fraction of the time as other medications. Results o… [+3626 chars] Read More